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OBJECTIVES: Analyze the economic impact of the A-H1N1 flu epidemic for the
health sector in Mexico in the 2009-2010 period, that resulted in the first pandemic
of the XXI century, in order to plan the resources provision and review policies
aimed to deal with similar future events. METHODS: The exercise had several
stages. First, a collect of the expenditures incurred by the health sector at federal
level between April 2009 and August 2010 was made. Second, the collected infor-
mation was classified into two areas of analysis: a) health care expenditures, and b)
additional costs from purchasing and application of vaccines, medical equipment,
drugs and health products, federal support to states, and national media cam-
paigns. Third, health care expenditure and expenditure by area of analysis was
estimated by aggregating all costs. RESULTS: Total federal expenditure related to
addressing the epidemic in the health sector was estimated in USD$ 733.3 million,
32% linked to health care and 93.7% exercised in 2009, corresponding to 11.2% of the
total health expenditure budget for this year. This expenditure involved medical
attention of 368 thousands patients, purchasing and application of 6.8 million of
anti-flu seasonal vaccines and 30 million of anti-AH1N1flu vaccines. For health
care, a total expenditure of USD$ 216.7 million was estimated, 80% exercised in
2009, that involves medical attention of 330 thousand patients. A total expenditure
of USD$ 516.3 million was estimated for additional costs, more than 99% exercised
in 2009. The main component of this area was the purchase and application of
A-H1N1 flu vaccine (USD$ 228.8 million). CONCLUSIONS: The exercise allows
knowing the mayor spending areas and generates evidence to strengthen the fi-
nancial and operational planning processes to face similar health events, such as
the need to anticipate resources and contingency funds in addition to administra-
tive and operational processes.
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OBJECTIVES: To calculate the average annual cost per ART in IMSS, ISSSTE and
MoH. To analyze the financial requirements for the provision of ART through the
Universal Access Program to Antiretroviral Drugs (PAUMA) lead for the MoH and its
implications for drug procurement policies at national level in the short and me-
dium terms.METHODS:We obtained data about patients under ART in 2007 for the
three main institutions mentioned and in 2009 only for MoH. Information was
analyzed to identify ART prescriptions according to official recommendations. Av-
erage annual cost of ART per patient and institution was estimated for 2007 and
2009. Projections of the financial requirements to ensure the provision of ART
through the PAUMA for the period 2010-2017 were estimated. Analysis was devel-
oped in STATA 9.2. RESULTS: In 2007 average annual cost of ART for the three main
institutions was MXP$64,800; per institution were as follow: ISSSTE MXP$74,300;
IMSS MXP$67,600 and MoH MXP$61,600. Information for the MoH indicates that
average annual cost of ART decreased between 2007 and 2009 by around 10.2% (in
2009 was MXP$55,300). First 20 ART options are prescribed to 80% of the patients
and represent around 73% of the total costs in 2009. Projections for PAUMA in the
period 2010-2017 indicate that on average annually 7,000 new patients require ART
and 5,000 deaths will occurred. Assuming new cases, deaths and prices of antiret-
roviral drugs remain constant the average annual increase in financial require-
ments for PAUMA to ensure ART in the period studied will be 5.6%. CONCLUSIONS:
Results generate evidence to strengthen the decision making, monitoring, contain-
ment costs, and purchase of antiretroviral drugs processes. It also provides infor-
mation to allow policy makers optimize the use of limited public resources to
support the demand for ART through the financial armor that contributes to main-
tain universal coverage, allowing the fulfillment of Goal 6 of the Millennium Devel-
opment Goals.
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OBJECTIVES:To estimate the economic impact of community acquired pneumonia
(CAP) in adults over 50 years of age in Argentina, Brazil, Chile, Colombia, Mexico,
and Venezuela.METHODS: Local data sources were used to estimate the number of
cases of hospitalized pneumonia cases from ICD-9 codes in the year 2009 in adults
50 years of age. CAP episodes were estimated from pneumonia proportionally by
age based on prior publications that compared ICD-9 coded hospitalizations to
confirmed CAP by chart review. Resource use was estimated from treatment guide-
lines and expert opinion and multiplied by local unit costs to derive total costs.
Indirect costs to patients and caregivers were estimated by average wages times
participation rate by age. Mortality cost was estimated by discounted life expec-
tancy times wage rates and participation rates by age group. Costs were converted
to USD by exchange rates to facilitate comparison. RESULTS: The average cost of
CAP hospitalizations in adults was (USD): Argentina$32,241; Brazil$29,457;
Chile$26,936; Colombia$23,656; Mexico$21,018; Venezuela$22,536. In adults
65 years old, indirect costs comprised 1.5% of cost associated with hospitaliza-
tions (range: 0.2% - 2.5%) and mortality costs comprised 16% (range: 3% - 24%). In
adults 65 direct costs were over 95% of episode costs. The total cost of CAP hos-
pitalizations in adults was (USD$Mil): Argentina$697; Brazil$3,624; Chile$445;
Colombia$347; Mexico$941; Venezuela$387. As a proportion of the total pop-
ulation, CAP hospitalizations cost approximately $74 per person 50 years old per
year (range $42-$108) and $148 per person over 65 per year (range $95-$235).
CONCLUSIONS: CAP hospitalizations represent a significant economic burden in
adults across Latin America countries. Nearly one quarter of the cost burden
among adults65 includes indirect costs, while the economic burden among older
patients is driven by direct costs and high incidence.
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OBJECTIVOS: La neumonía nosocomial (NN) es la segunda causa más frecuente de
infección intrahospitalaria, la infección más frecuentemente adquirida en la uni-
dad de cuidados intensivos (UCI) y la primera causa de mortalidad por infecciones
intrahospitalarias. El objetivo de esta investigación fue estimar el costo-efectividad
del uso de linezolid en el tratamiento de la NN en comparación con el uso de
vancomicina y teicoplanina, desde la perspectiva del Instituto Mexicano del Seguro
Social (IMSS). METODOLOGÍAS: Se construyó un árbol de decisiones que compara
el uso de linezolid inyectable, seguido por linezolid oral (600mg dos veces/día),
vancomicina inyectable (1000mg dos veces/día) y teicoplanina inyectable (400mg
dos veces el primer día, días subsecuentes: 400mg) en el tratamiento de NN (hori-
zonte temporal: 38 días). Se evalúan la tasa de éxito microbiológico, los días de
estancia hospitalaria (en piso y UCI) y los costos médicos directos. Se realizó una
revisión de literatura para extraer la tasa de respuesta. La relación de insumos
(laboratorios, consultas y medicamentos) y procedimientos, así como el manejo
hospitalario se extrajó de la literatura y se complementó con opinión de expertos.
Los costos corresponden al IMSS para el año 2010. Se realizó análisis de sensibilidad
probabilístico. RESULTADOS: La tasa de éxito microbiológico del tratamiento con
linezolid fue de 64%, 59.5% con vancomicina (p0.336) y 44.1% con teicoplanina
(p0.001). Esto se refleja en una menor estancia en UCI, con 17.4 días para linezolid,
21.26 días con vancomicina y 21.82 días para teicoplanina. El costo total de trata-
miento con linezolid fue $777,873.14, siendo menor respecto del de vancomicina
($865,186.96) y teicoplanina ($931,983.09). Las curvas de aceptabilidad muestran
que linezolid es costo ahorrador con respecto a vancomicina o teicoplanina.
CONCLUSIONES: En el tratamiento de las NN en el contexto del IMSS, linezolid
presenta dominacia débil sobre vancomicina y dominancia absoluta sobre teico-
planina.
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OBJECTIVES: In 2009, it was estimated that there were 12.000 to 28.000 deaths in
Latin America related to Streptococcus pneumonia infections in pediatric popula-
tion under 5 years old. Currently, in El Salvador, Prevenar 7 (PCV-7) is the anti-
pneumococcal vaccine used. The aim of this study was to estimate the cost-effec-
tiveness and cost-utility of immunization strategies based on pneumococcal
conjugated vaccines (PCVs) in El Salvador, from an institutional perspective.
METHODS:A decision tree model was used to asses economic and health impact of
PCVs in children under 2 years old. The alternatives compared were: no vaccination
(comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were: child
illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2009 $US) and epidemiology (data from 2009) were obtained from El
Salvador=s Ministry of Health database. The model included vaccine dosage sched-
ules approved in WHO prequalification and/or El Salvador MoH calendar at the
time of data collection (dec-2010). Univariate sensitivity analysis was performed.
The time horizon was one year and the discount rate was 3%. RESULTS: Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained the
highest number of QALYs (898) against PCV-10 (637) and PCV-7 (460). PCV-13 pre-
vented 359 illnesses and gained 998 LYs. PCV-10 and PCV-7 prevented 257 and 228
illnesses and gained 707 and 511 LY=s, respectively. These results were robust to
variations in herd immunity and impact adjustments of PCV10 immunogenicity.
CONCLUSIONS: In El Salvador, immunization strategies based on 7, 10 and 13-
valent PCV=s would be cost-saving interventions. Health outcomes and savings of
PCV-13 are greater than those estimated for 7 and 10-valent PCV=s.
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OBJECTIVOS: Traducir los beneficios clínicos de extender el período de profilaxis
con Valganciclovir de 100 a 200 días en un análisis de costo-efectividad de largo
plazo en la etapa postrasplante en pacientes con alto riesgo de enfermedad por
Citomegalovirus (CMV) (D / R). METODOLOGÍAS: Se utilizó un Modelo Markov
para simular los costos de los diferentes estadios de la enfermedad. Los horizontes
temporales evaluados son: menor a un año, un año, cinco años y diez años. La
población modelada son pacientes receptores de trasplante renal (RTR) con alto
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